S. 4535 (117th Congress)

FDASRA Act of 2022

1/7

FDASRA Act of 2022 — Display Title · Jan 3, 2025
Food and Drug Administration Simple Reauthorization Act of 2022 — Short Title as Introduced · Jul 20, 2022
Biosimilar User Fee Amendments of 2022 — Short Title as Introduced (portions) · Jul 20, 2022
Generic Drug User Fee Amendments of 2022 — Short Title as Introduced (portions) · Jul 20, 2022
Medical Device User Fee Amendments of 2022 — Short Title as Introduced (portions) · Jul 20, 2022
Prescription Drug User Fee Amendments of 2022 — Short Title as Introduced (portions) · Jul 20, 2022
A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes. — Official Title as Introduced · Jul 20, 2022

Status In Committee

Sponsor Richard Burr

Citation 117-S-4535

Actions 2

Introduced Jul 14th, 2022

Cosponsors

Last Action Jul 14th, 2022

Policy Area Health

✓

Introduced Senate Jul 14

Senate

House

President

Enacted

Summary

AI Guide

What this bill does

Loading AI analysis…

Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022 This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.

Actions

Senate

INTRODUCED	INTRODUCED					Jul 14, 2022
ON FLOOR	REFERRED TO COMMITTEE

S 4348	FDASLA Act of 2022	Related	—	—
HR 7667	Food and Drug Amendments of 2022	Related	—	—
HR 6833	Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023	Related	—	—